FDAnews
www.fdanews.com/articles/197016-fda-grants-novartis-tabrecta-accelerated-approval-for-lung-cancer

FDA Grants Novartis’ Tabrecta Accelerated Approval for Lung Cancer

May 8, 2020

The FDA granted Novartis accelerated approval for Tabrecta (capmatinib) for treatment for adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Tabrecta is the first FDA-approved therapy to treat NSCLC with specific mutations that can cause cancer metastasis, including those that lead to mesenchymal-epithelial transition (MET).

The drug received breakthrough therapy, priority review and orphan drug designations.

View today's stories